Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 3/20 | 0.77 |
| ▸ | UBE2N | P61088 | 2/20 | 0.77 |
| ▸ | GLA | P06280 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.74 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.74 |
| ▸ | PDE1A | P54750 | 1/20 | 0.71 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.71 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17750785 | 0.93 | LMNA (0.89) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL11014928 | 0.89 | POLB (0.83) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL556216 | 0.89 | SMN1; SMN2 (0.80) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL23974582 | 0.89 | SMN1; SMN2 (0.80) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL17786242 | 0.87 | ALDH1A1 (1.00) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL20561174 | 0.87 | LMNA (1.00) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL20561098 | 0.87 | LMNA (0.80) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL555718 | 0.87 | SMN1; SMN2 (0.76) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL20011033 | 0.87 | SMN1; SMN2 (0.76) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL22521806 | 0.86 | SMN1; SMN2 (0.76) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744465-A | Synthetic method of high-purity high-yield theophylline | HEFEI PINGGUANG PHARMACEUTICAL CO LTD | 2015-07-01 | — | — | CN | claimed |
| EP-0222414-A2 | Novel organic selenium compounds | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1987-05-20 | — | — | EP | claimed |
| US-20240392273-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-3624846-B1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A COMBINATION OF NICOTINIC ACID AND TRYOPTOPHAN | BHAMIS RES LABORATORY PVT LTD (IN) | 2024-08-07 | — | — | EP | disclosed |
| EP-4401758-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Takeda Pharmaceutical Company Limited (JP) | 2024-07-24 | — | — | EP | disclosed |
| CN-118139636-A | Delivery of promoted concentrated antibody formulations using hyaluronidase | 武田药品工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-11 | — | — | US | disclosed |
| US-11738082-B2 | High concentration protein formulations with reduced viscosity | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2023-08-29 | — | — | US | disclosed |
| WO-2023042096-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | WO | disclosed |
| CN-113677678-A | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113677679-A | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-0708781-A1 | A 3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0680479-A1 | METHOD FOR CONVERTING A XANTHINE RING OR DERIVATIVES THEREOF INTO DIALKYLAMINO-XANTHINE DERIVATIVES | S.A. NYCOMED CHRISTIAENS N.V. (BE) | 1995-11-08 | — | — | EP | disclosed |
| WO-1995002604-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994017064-A1 | METHOD FOR CONVERTING A XANTHINE RING OR DERIVATIVES THEREOF INTO DIALKYLAMINO-XANTHINE DERIVATIVES | S.A. NYCOMED CHRISTIAENS N.V. (BE) | 1994-08-04 | — | — | WO | disclosed |
| US-4942143-A | Imidazothiadiazine derivatives, and their use as medicaments | HOECHST JAPAN LIMITED (JP) | 1990-07-17 | — | — | US | disclosed |
| US-4824955-A | ANTITUMOR AGENTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0286041-A1 | Imidazothiadiazine derivatives, a process for preparing the same and their use as medicaments | HOECHST JAPAN LIMITED (JP) | 1988-10-12 | — | — | EP | disclosed |
| EP-0222414-A2 | Novel organic selenium compounds | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1987-05-20 | — | — | EP | disclosed |
| EP-0222414-A2 | Novel organic selenium compounds | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738082-B2 | High concentration protein formulations with reduced viscosity | ALB, TTR, MAX | ADORA2B 3824/4885SMN1; SMN2 320/4885RXFP1 1610/4885 |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | ADORA2B 3824/4885SMN1; SMN2 320/4885RXFP1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.